Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCTL | Q9NXS2 | 3/20 | 0.33 |
| ▸ | CCNC | P24863 | 2/20 | 0.33 |
| ▸ | CDK8 | P49336 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7980168 | 0.93 | QPCTL (0.32) | QPCTL | |
| Hydrochloric Acid SCHEMBL1418565 | 0.92 | QPCTL (0.32) | QPCTL | |
| SCHEMBL7988061 | 0.86 | CCNC (0.35) | CCNCCDK8 | |
| SCHEMBL7981725 | 0.85 | CYP1A2 (0.34) | CCNCCDK8 | |
| SCHEMBL1417681 | 0.81 | TGFBR1 (0.39) | — | |
| SCHEMBL7970863 | 0.81 | CCNC (0.38) | CCNCCDK8MAPT | |
| SCHEMBL7980874 | 0.81 | CCNC (0.38) | CCNCCDK8MAPT | |
| SCHEMBL7984509 | 0.81 | NPC1 (0.34) | CCNCCDK8 | |
| SCHEMBL7971540 | 0.80 | ALDH1A1 (0.37) | MAPT | |
| SCHEMBL1417973 | 0.80 | FGFR2 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| EP-2298747-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2011-03-23 | — | — | EP | disclosed |
| WO-2010001946-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | アステラス製薬株式会社 (JP) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | HSD11B1, HSD11B2, HSD3B1 | QPCTL 4276/4885CCNC 4625/4885CDK8 3503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.